This Bull Market Indicator called NVDA at $116

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Jason Rhodes Biography and Net Worth

Director of Generation Bio

Jason Rhodes is a partner and focuses on creating and building novel therapeutics companies.

Jason is the chairman and was the founding CEO of Generation Bio (NASDAQ: GBIO) and Dyne Therapeutics (NASDAQ: DYN). He is also on the boards of Replimune (NASDAQ: REPL), Gemini Therapeutics (NASDAQ: GMTX), Accent Therapeutics, Be Biopharma, K36, Rectify Pharmaceuticals, and Third Harmonic Bio. He was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020.

Previously, Jason held leadership positions at Epizyme (NASDAQ: EPZM), where he was President and built the company from early stage research into the clinic and through a successful IPO in 2013, and at Alnylam Pharmaceuticals (NASDAQ: ALNY), where he led business development. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer.

Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.

He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council. Jason spends his free time mountain biking and loudly watching Spanish fútbol with his family.

What is Jason P. Rhodes' net worth?: The estimated net worth of Jason P. Rhodes is at least $21,867.94 as of November 14th, 2024. Ms. Rhodes owns 15,962 shares of Generation Bio stock worth more than $21,868 as of November 24th. This net worth evaluation does not reflect any other investments that Ms. Rhodes may own. Learn More about Jason P. Rhodes' net worth.
How do I contact Jason P. Rhodes?: The corporate mailing address for Ms. Rhodes and other Generation Bio executives is 301 BINNEY STREET, CAMBRIDGE MA, 02142. Generation Bio can also be reached via phone at 617-655-7500 and via email at [email protected]. Learn More on Jason P. Rhodes' contact information.
Has Jason P. Rhodes been buying or selling shares of Generation Bio?: Jason P. Rhodes has not been actively trading shares of Generation Bio within the last three months. Most recently, Jason P. Rhodes sold 16,586 shares of the business's stock in a transaction on Wednesday, September 29th. The shares were sold at an average price of $24.59, for a transaction totalling $407,849.74. Learn More on Jason P. Rhodes' trading history.
Who are Generation Bio's active insiders?: Generation Bio's insider roster includes Douglas Kerr (Insider), Geoff McDonough (CEO), Jason Rhodes (Director), Evan Spiegel (CEO), and Matthew Stanton (Insider). Learn More on Generation Bio's active insiders.
Are insiders buying or selling shares of Generation Bio?: In the last twelve months, Generation Bio insiders bought shares 2 times. They purchased a total of 12,637 shares worth more than $19,159.34. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 9,164 shares worth more than $22,370.96. The most recent insider tranaction occured on July, 1st when COO Antoinette Paone sold 6,719 shares worth more than $18,410.06. Insiders at Generation Bio own 21.1% of the company. Learn More about insider trades at Generation Bio.
Information on this page was last updated on 7/1/2024.

Jason P. Rhodes Insider Trading History at Generation Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/29/2021	Sell	16,586	$24.59	$407,849.74
9/27/2021	Sell	51,389	$25.70	$1,320,697.30
9/24/2021	Sell	28,916	$25.84	$747,189.44
9/22/2021	Sell	30,617	$25.89	$792,674.13
6/23/2021	Sell	62,609	$25.36	$1,587,764.24
6/21/2021	Sell	63,892	$24.84	$1,587,077.28
4/14/2021	Sell	23,413	$26.61	$623,019.93
4/12/2021	Sell	74,124	$26.15	$1,938,342.60
4/8/2021	Sell	43,550	$28.50	$1,241,175.00

Jason P. Rhodes Buying and Selling Activity at Generation Bio

Generation Bio Company Overview

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.37

$1.29

$1.48

50 Day Range

MA: $2.24

$1.32

$2.86

2 Week Range

Now: $1.37

$1.10

$4.65

Volume

328,434 shs

Average Volume

167,402 shs

Market Capitalization

$91.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82